A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY OF KETOCONAZOLE FOR REDUCING THE RISK OF OVARIAN HYPERSTIMULATION SYNDROME

In order to evaluate the role ofketoconazole in the prevention of ovarian hyperstimulation syndrome (OHSS) in women with polycystic ovary syndrome (PCOS) undergoing ovarian stimulation with gonadotropins, a prospective, randomized, double-blind, placebo controlled study was done on one-hundred and nine PCOS women that had been refeiTed to be treated by gonadotropins. Alll09 women were assigned for random allocation. Group A (50 patients) received two ampoules ofhMG beginning on day 2 or 3 of the cycle and ketoconazole (50 mg/every 48 hours) starting on the first day ofhMG treatment. Group B (51 patients) received the same protocol ofhMG combined with one tablet of placebo every 48 hours. Main outcome measures were follicular development, E2levels, and pregnancy rate. The total number ofhMG ampoules and duration oftreatment to attain ovarian stimulation was higher in group A (pConclusion